Showing results (171-180 of 239) with videos related to
Sort By:
Pageof 24
International Journal of Cancer|September 25, 2018
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastomaSarah Harris-Bookman, Dimitrios Mathios, Allison M Martin, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|July 25, 2017
Melanoma subtypes demonstrate distinct PD-L1 expression profilesGenevieve J Kaunitz, Tricia R Cottrell, Mohammed Lilo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II StudyErika J Lampert, Alexandra Zimmer, Michelle Padget, et al.JAMA Oncology|March 10, 2017
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung CancerDavid L Rimm, Gang Han, Janis M Taube, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.Journal for Immunotherapy of Cancer|December 25, 2025
AstroID resource: a scalable, relational database structure for longitudinal biomarker discoveryElizabeth M Will, Benjamin F Green, Scott Carey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.Journal of Translational Medicine|March 5, 2024
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockadeShuming Chen, Tracee L McMiller, Abha Soni, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and VaccinationChristopher M Jackson, Christina M Kochel, Christopher J Nirschl, et al.Pageof 24